Patents by Inventor Ruth Lupu

Ruth Lupu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USING FATTY ACID SYNTHASE INHIBITORS TO TREAT FIBROSIS
    Publication number: 20220313654
    Abstract: This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and/or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).
    Type: Application
    Filed: February 16, 2022
    Publication date: October 6, 2022
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Edward B. Leof, Ruth Lupu, Jeong-Han Kang, Mi-Yeon Jung
  • USING FATTY ACID SYNTHASE INHIBITORS TO TREAT FIBROSIS
    Publication number: 20190070145
    Abstract: This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and/or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).
    Type: Application
    Filed: March 22, 2017
    Publication date: March 7, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Edward B. Leof, Ruth Lupu, Jeong-Han Kang, Mi-Yeon Jung
  • Materials and methods for treating and preventing Her-2/neu overexpressing, FAS-elevated cancer cells
    Publication number: 20070207975
    Abstract: The invention provides methods for treating cancer cells overexpressing Her-2/neu, the product of the erbB-2 gene, comprising administering a therapeutically effective amount of an unsaturated fatty acid. The cancer cells amenable to treatment exhibit relatively elevated activity levels of fatty acid synthase. Exemplary fatty acids useful in the methods of the invention include ?-9 monounsaturated fatty acids (e.g., oleic acid), ?-6 polyunsaturated fatty acids (e.g., ?-linolenic acid) and ?-3 polyunsaturated fatty acids (e.g., ?-linolenic acid). The invention also provides methods of preventing cancer comprising administering a prophylactically effective amount of a fatty acid and kits for preventing and/or treating cancer comprising a fatty acid and a conventional anti-cancer therapeutic.
    Type: Application
    Filed: January 9, 2007
    Publication date: September 6, 2007
    Applicant: EVANSTON NORTHWESTERN HEALTHCARE
    Inventors: Javier Menendez, Ruth Lupu
  • Ligand growth factor gp30 that binds to the erbB-2 receptor protein and induces cellular responses
    Patent number: 6040290
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: March 21, 2000
    Assignee: Georgetown University
    Inventors: Marc E. Lippman, Ruth Lupu
  • Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
    Patent number: 5874528
    Abstract: The present invention relates to blocking peptides which are capable of binding to ligands for the erbB-2 receptor or the epidermal growth factor receptor (EGFR). The blocking peptides of the invention are used to detect the presence of such ligand molecules. In addition, the blocking peptides are useful in inhibiting or preventing the growth of adenocarcinoma cells which express the erbB-2 receptor or the EGFR.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: February 23, 1999
    Assignee: Georgetown University
    Inventors: Ruth Lupu, Marc E. Lippman
  • Antibodies to ligand growth factors
    Patent number: 5869618
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: February 9, 1999
    Inventors: Marc E. Lippman, Ruth Lupu
  • Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
    Patent number: 5578482
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 kDa glycoprotein effective to inhibit the growth of said cells.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: November 26, 1996
    Assignee: Georgetown University
    Inventors: Marc E. Lippman, Ruth Lupu